These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15742639)

  • 21. Control of foot and mouth disease: the experience of the Americas.
    Correa Melo E; López A
    Rev Sci Tech; 2002 Dec; 21(3):695-8, 689-94. PubMed ID: 12523707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiplexed detection of antibodies to nonstructural proteins of foot-and-mouth disease virus.
    Perkins J; Clavijo A; Hindson BJ; Lenhoff RJ; McBride MT
    Anal Chem; 2006 Aug; 78(15):5462-8. PubMed ID: 16878883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk evaluation of nonvaccinated, weaned calves transported through areas under systematic foot and mouth disease (FMD) vaccination.
    Leanes LF; Abbiati NN; Pereyra AM; Maizon DO
    Prev Vet Med; 2011 Feb; 98(2-3):133-41. PubMed ID: 21071104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: Use in emergency outbreak response.
    Golde WT; Pacheco JM; Duque H; Doel T; Penfold B; Ferman GS; Gregg DR; Rodriguez LL
    Vaccine; 2005 Dec; 23(50):5775-82. PubMed ID: 16153756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. International approach to eradication and surveillance for foot-and-mouth disease in the Americas.
    Rodriguez-Torres JG
    Ann N Y Acad Sci; 2000; 916():194-8. PubMed ID: 11193621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination as a control measure during the outbreak of foot-and-mouth disease in 2000 in Korea.
    Park JH; Park JY; Kim YJ; Oem JK; Lee KN; Kye SJ; Joo YS
    Dev Biol (Basel); 2004; 119():63-70. PubMed ID: 15742619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of immune responses after intra-typic heterologous and homologous vaccination against foot-and-mouth disease virus infection in pigs.
    Eblé PL; de Bruin MG; Bouma A; van Hemert-Kluitenberg F; Dekker A
    Vaccine; 2006 Feb; 24(9):1274-81. PubMed ID: 16289709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Production and application of recombinant antibodies to foot-and-mouth disease virus non-structural protein 3ABC.
    Foord AJ; Muller JD; Yu M; Wang LF; Heine HG
    J Immunol Methods; 2007 Apr; 321(1-2):142-51. PubMed ID: 17328909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals.
    Grubman MJ
    Biologicals; 2005 Dec; 33(4):227-34. PubMed ID: 16289996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intradermal vaccination of pigs against FMD with 1/10 dose results in comparable vaccine efficacy as intramuscular vaccination with a full dose.
    Eblé PL; Weerdmeester K; van Hemert-Kluitenberg F; Dekker A
    Vaccine; 2009 Feb; 27(8):1272-8. PubMed ID: 19114077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antigen and vaccine banks: technical requirements and the role of the european antigen bank in emergency foot and mouth disease vaccination.
    Lombard M; Füssel AE
    Rev Sci Tech; 2007 Apr; 26(1):117-34. PubMed ID: 17633297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cedivac-FMD can be used according to a marker vaccine principle.
    Chénard G; Selman P; Dekker A
    Vet Microbiol; 2008 Apr; 128(1-2):65-71. PubMed ID: 18035508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategy for the control of foot-and-mouth disease in Southeast Asia (SEAFMD).
    Edwards JR
    Dev Biol (Basel); 2004; 119():423-31. PubMed ID: 15742655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune responses of pigs to commercialized emulsion FMD vaccines and live virus challenge.
    Chen SP; Lee MC; Sun YF; Cheng IC; Yang PC; Lin YL; Jong MH; Robertson ID; Edwards JR; Ellis TM
    Vaccine; 2007 May; 25(22):4464-9. PubMed ID: 17445957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection of guinea pigs and swine by a recombinant adenovirus expressing O serotype of foot-and-mouth disease virus whole capsid and 3C protease.
    Lu Z; Bao H; Cao Y; Sun P; Guo J; Li P; Bai X; Chen Y; Xie B; Li D; Liu Z; Xie Q
    Vaccine; 2008 Dec; 26 Suppl 6():G48-53. PubMed ID: 19178894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of an epitope-blocking-enzyme-linked immunosorbent assay to differentiate between animals infected with and vaccinated against foot-and-mouth disease virus.
    Oem JK; Chang BS; Joo HD; Yang MY; Kim GJ; Park JY; Ko YJ; Kim YJ; Park JH; Joo YS
    J Virol Methods; 2007 Jun; 142(1-2):174-81. PubMed ID: 17336400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of the immune response to FMDV structural and non-structural proteins in cattle in Argentina by the combined use of liquid phase and 3ABC-ELISA tests.
    Robiolo B; Seki C; Fondevilla N; Grigera P; Scodeller E; Periolo O; La Torre J; Mattion N
    Vaccine; 2006 Feb; 24(7):997-1008. PubMed ID: 16171905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Bayesian evaluation of six diagnostic tests for foot-and-mouth disease for vaccinated and non-vaccinated cattle.
    Engel B; Buist W; Orsel K; Dekker A; de Clercq K; Grazioli S; van Roermund H
    Prev Vet Med; 2008 Aug; 86(1-2):124-38. PubMed ID: 18455817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategy for the control of foot-and-mouth disease in Uruguay.
    Ugarte R
    Dev Biol (Basel); 2004; 119():415-21. PubMed ID: 15742654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Foot and mouth disease virus transmission among vaccinated pigs after exposure to virus shedding pigs.
    Orsel K; de Jong MC; Bouma A; Stegeman JA; Dekker A
    Vaccine; 2007 Aug; 25(34):6381-91. PubMed ID: 17658199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.